• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Allergy to Omalizumab: Lessons from a Reaction to the Coronavirus 2019 Vaccine
Intern Med. 2023 Feb 1. doi: 10.2169/internalmedicine.1169-22. Online ahead of print.ABSTRACTOmalizumab can cause hypersensitivity reactions. We herein report the first case of an 18-year-old woman with refractory cough-predominant asthma that correlated with allergic reactions caused by omalizumab and the coronavirus disease 2019 (COVID-19) vaccine. The patient developed angioedema after taking omalizumab. She had previously experienced intense coughing immediately after receiving a COVID-19 vaccine. A skin prick test was positive for polysorbate 20, which was probably the cause of the allergic reactions to omalizumab and...
Source: Internal Medicine - February 1, 2023 Category: Internal Medicine Authors: Takeshi Matsumoto Yumiko Sakurai Takahiro Fujiki Yusuke Kusakabe Emi Nakayama Ayaka Tanaka Naoki Yamamoto Kensaku Aihara Shinpachi Yamaoka Michiaki Mishima Source Type: research

What to Know About the Latest Advances in Managing Severe Asthma
Graphs and charts don’t always tell the whole story. Numbers can be deceiving. But anyone who looks at U.S. trends in asthma mortality can see, without squinting, that things are moving in the right direction. A 2019 analysis in the American Journal of Respiratory and Critical Care Medicine found that from 1999 to 2015, asthma mortality fell by 43%. “The decrease in asthma-related mortality was consistent in both sexes and in all race groups, with the largest decrease in patients older than 65 years,” the authors concluded. Figures from the U.S. Centers for Disease Control and Prevention indicate that the...
Source: TIME: Health - June 23, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news

From the Pages of AllergyWatch
For this edition of “From the Pages of AllergyWatch,” I have chosen articles that focus on asthma, the theme of this month's Annals of Allergy, Asthma& Immunology. The first article, with comments from Dr Hernandez-Trujillo, compares the characteristics and cytokine profiles of patients with coronavirus disease 2019 (COVID-19) with and without asthma. The next, with comments from Dr Oppenheimer, presents data from a post hoc analysis of studies with individuals with asthma treated with omalizumab.
Source: Annals of Allergy, Asthma and Immunology - January 4, 2022 Category: Allergy & Immunology Authors: Stanley M. Fineman, Vivian Hernandez-Trujillo, John J. Oppenheimer, Bradley E. Chipps Tags: Special Series Source Type: research

Severe asthma biologic treatment in the era of COVID-19 - case series
Conclusions: Only a minority of this population tested positive for COVID-19 and none of them developed serious disease, supporting the evidence that both severe type-2 asthma and its targeted treatment do not convey increased risk for disease. However, additional studies regarding long-term complications should also be performed.
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Costa, P. M. N., Loureiro, C. C. Tags: Allergy and immunology Source Type: research